Top ▲


Click here for help

Immunopharmacology Ligand target has curated data in GtoImmuPdb

Target id: 1876

Nomenclature: CD27

Systematic Nomenclature: TNFRSF7

Family: Tumour necrosis factor (TNF) receptor family

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 260 12p13.31 CD27 CD27 molecule
Mouse 1 250 6 59.32 cM Cd27 CD27 antigen
Rat - - Cd27 CD27 molecule
Previous and Unofficial Names Click here for help
CD antigen 27 | CD27 molecule | Tp55
Database Links Click here for help
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
Natural/Endogenous Ligands Click here for help
CD70 {Sp: Human}
Adaptor proteins (Human)
Other Binding Ligands
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Value Parameter Reference
CD70 {Sp: Human} Peptide Ligand is endogenous in the given species Hs - - -
Immunopharmacology Comments
CD27 (TNFRSF7) is a co-stimulatory immune checkpoint molecule that is expressed on various immune cells, including T cells and NK (natural killer) cells. The endogenous ligand for CD27 is CD70. CD27 interacts with various TRAF adaptor proteins and apoptosis regulatory protein SIVA (SIVA1). It has been recognized as playing an important role in priming, enhancing and sustaining a productive anti-cancer (CD8 T cell) adaptive immune response. CD27 is an immuno-oncology target [1-2]. The agonistic CD27 antibody varlilumab (CDX-1127) is being evaluated for efficacy against solid cancers and lymphomas in early phase clinical trials. Click here to link to's list of registered varlilumab trials.
Immuno Process Associations
Immuno Process:  T cell (activation)
Immuno Process:  B cell (activation)
Immuno Process:  Immune regulation
Immuno Process:  Immune system development
Immuno Process:  Cytokine production & signalling
Immuno Process:  Cellular signalling
Immuno Process:  Chemotaxis & migration


Show »

1. Buchan SL, Rogel A, Al-Shamkhani A. (2018) The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood, 131 (1): 39-48. [PMID:29118006]

2. van de Ven K, Borst J. (2015) Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy, 7 (6): 655-67. [PMID:26098609]


Show »

How to cite this page